JP6479670B2 - ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法 - Google Patents

７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法

Info

Publication number
JP6479670B2
JP6479670B2 JP2015540801A JP2015540801A JP6479670B2 JP 6479670 B2 JP6479670 B2 JP 6479670B2 JP 2015540801 A JP2015540801 A JP 2015540801A JP 2015540801 A JP2015540801 A JP 2015540801A JP 6479670 B2 JP6479670 B2 JP 6479670B2
Authority
JP
Japan
Prior art keywords
amino
alkyl
compound
heterocyclyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015540801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015535290A (ja
JP2015535290A5 (enExample
Inventor
イエ，ケチャン
Original Assignee
エモリー ユニバーシティー
エモリー ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エモリー ユニバーシティー, エモリー ユニバーシティー filed Critical エモリー ユニバーシティー
Publication of JP2015535290A publication Critical patent/JP2015535290A/ja
Publication of JP2015535290A5 publication Critical patent/JP2015535290A5/ja
Application granted granted Critical
Publication of JP6479670B2 publication Critical patent/JP6479670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/38—2,3-Dihydro derivatives, e.g. isoflavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015540801A 2012-11-05 2013-11-01 ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法 Active JP6479670B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261722339P 2012-11-05 2012-11-05
US61/722,339 2012-11-05
US201361845399P 2013-07-12 2013-07-12
US61/845,399 2013-07-12
PCT/US2013/067972 WO2014071134A1 (en) 2012-11-05 2013-11-01 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019020153A Division JP2019089817A (ja) 2012-11-05 2019-02-06 ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法

Publications (3)

Publication Number Publication Date
JP2015535290A JP2015535290A (ja) 2015-12-10
JP2015535290A5 JP2015535290A5 (enExample) 2016-12-08
JP6479670B2 true JP6479670B2 (ja) 2019-03-06

Family

ID=50628080

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015540801A Active JP6479670B2 (ja) 2012-11-05 2013-11-01 ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法
JP2019020153A Pending JP2019089817A (ja) 2012-11-05 2019-02-06 ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法
JP2020206038A Pending JP2021050230A (ja) 2012-11-05 2020-12-11 ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019020153A Pending JP2019089817A (ja) 2012-11-05 2019-02-06 ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法
JP2020206038A Pending JP2021050230A (ja) 2012-11-05 2020-12-11 ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法

Country Status (8)

Country Link
US (3) US9682948B2 (enExample)
EP (2) EP3369730B1 (enExample)
JP (3) JP6479670B2 (enExample)
CN (2) CN104812744B (enExample)
AU (3) AU2013337742B2 (enExample)
CA (1) CA2890075C (enExample)
ES (1) ES2823237T3 (enExample)
WO (1) WO2014071134A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021050230A (ja) * 2012-11-05 2021-04-01 エモリー ユニバーシティー ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11998516B2 (en) 2011-03-07 2024-06-04 Tonix Pharma Holdings Limited Methods and compositions for treating depression using cyclobenzaprine
EP2877461B1 (en) 2012-07-27 2018-05-09 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
JP2021505629A (ja) * 2017-12-11 2021-02-18 トニックス ファーマ ホールディングス リミテッド 認知症および神経変性状態における興奮、精神病および認知機能低下のためのシクロベンザプリン処置
CN108299367B (zh) * 2018-01-26 2022-04-12 南阳师范学院 一种芹菜苷元氨基甲酸酯类化合物、其制备方法及应用
EP3787617A4 (en) * 2018-05-03 2021-09-08 Georgia State University Research Foundation Inc. RESPIRATORY SYNCYTIAL VIRUS (RSV) REPLICATION INHIBITORS AND THEIR USES
CN110577532B (zh) * 2018-06-08 2022-06-03 江苏威凯尔医药科技有限公司 原肌球蛋白受体激酶抑制剂及其制备方法和应用
EP3831821A4 (en) * 2018-08-01 2022-05-11 Shaanxi Micot Technology Limited Company Compound for treating nervous system diseases and use thereof
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
CN109574975B (zh) * 2019-01-14 2023-07-14 上海博芮健制药有限公司 7,8-二羟基黄酮衍生物的晶型及其制备方法和应用
WO2020154434A1 (en) * 2019-01-24 2020-07-30 Pharmatrophix, Inc. Compositions and methods for treating and preventing cognitive dysfunction
CN111825649A (zh) * 2019-04-15 2020-10-27 上海博芮健制药有限公司 7,8-二羟基黄酮衍生物的纯化方法
CN114075162A (zh) * 2020-08-20 2022-02-22 上海博芮健制药有限公司 7,8-二羟基黄酮衍生物的晶型b及其制备方法、应用
CN112168976B (zh) * 2020-10-15 2022-11-04 天津科技大学 一种黄酮衍生物前药及合成和作为抗肿瘤药物的应用
CN118369095A (zh) * 2021-07-15 2024-07-19 爱默蕾大学 用取代的黄酮治疗骨病的方法
CN118251415A (zh) * 2021-10-29 2024-06-25 清华大学 用于治疗或诊断精神分裂症的方法和产品
CA3237199A1 (en) 2021-11-02 2023-05-11 Flare Therapeutics Inc. Pparg inverse agonists and uses thereof
TWI887826B (zh) * 2022-11-02 2025-06-21 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
WO2002024676A1 (en) * 2000-09-21 2002-03-28 Teva Pharmaceuticals Industries, Ltd. N-disubstituted carbamoyloxy flavones
US20020160983A1 (en) * 2001-03-16 2002-10-31 Alberto Bargiotti Substituted benzopyranones as telomerase inhibitors
EP1383465B1 (en) 2001-03-29 2011-08-10 Michael Davis Acute pharmacologic augmentation of psychotherapy with d-cycloserine
US20030125264A1 (en) * 2001-12-29 2003-07-03 Kimberly-Clark Worldwide, Inc. Methods For Treating Wounds
PT1846394E (pt) * 2005-02-04 2012-01-05 Astrazeneca Ab Derivados de pirazolilaminopiridina úteis como inibidores da quinase
WO2007148158A1 (en) 2006-06-21 2007-12-27 Piramal Life Sciences Limited Enantiomerically pure flavone derivatives for the treatment of poliferative disorders and processes for their preparation
CZ300589B6 (cs) 2006-09-04 2009-06-24 Univerzita Palackého Deriváty 2-fenyl-3-hydroxychinolin-4(1H)-onu a zpusob jejich prípravy a použití
CN102143744B (zh) * 2008-07-25 2016-08-31 爱默蕾大学 7,8-二羟基黄酮及其衍生物在制备治疗抑郁的药物中的用途
WO2010107866A2 (en) 2009-03-20 2010-09-23 Emory University Catecholamine derivatives for obesity and neurological disorders
CN101591319B (zh) * 2009-06-22 2011-12-21 复旦大学 黄酮类衍生物及其在制备药物组合物中的用途
EP2473495A1 (en) * 2009-09-18 2012-07-11 Almac Discovery Limited Pharmaceutical compounds
CN105566272A (zh) * 2010-06-09 2016-05-11 爱默蕾大学 TrkB激动剂及其用途
WO2014071134A1 (en) * 2012-11-05 2014-05-08 Emory University 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021050230A (ja) * 2012-11-05 2021-04-01 エモリー ユニバーシティー ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法

Also Published As

Publication number Publication date
AU2019213454B2 (en) 2020-07-09
US20150274692A1 (en) 2015-10-01
JP2019089817A (ja) 2019-06-13
ES2823237T3 (es) 2021-05-06
EP2914585A4 (en) 2016-03-23
AU2018201060A1 (en) 2018-03-08
AU2013337742A1 (en) 2015-05-21
EP3369730B1 (en) 2020-08-05
EP3369730A1 (en) 2018-09-05
US10526303B2 (en) 2020-01-07
CN107868071A (zh) 2018-04-03
AU2019213454A1 (en) 2019-08-29
CA2890075A1 (en) 2014-05-08
CN104812744B (zh) 2017-12-01
US20170305876A1 (en) 2017-10-26
AU2018201060B2 (en) 2019-05-16
EP2914585A1 (en) 2015-09-09
CA2890075C (en) 2021-01-05
WO2014071134A1 (en) 2014-05-08
JP2015535290A (ja) 2015-12-10
JP2021050230A (ja) 2021-04-01
US9975868B2 (en) 2018-05-22
EP2914585B1 (en) 2018-03-07
CN107868071B (zh) 2021-07-20
CN104812744A (zh) 2015-07-29
US20180186762A1 (en) 2018-07-05
US9682948B2 (en) 2017-06-20
AU2013337742B2 (en) 2017-11-23

Similar Documents

Publication Publication Date Title
JP6479670B2 (ja) ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法
US20240262840A1 (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
CN104487429B (zh) 杂环黄酮衍生物、组合物及与其相关的方法
US20200179336A1 (en) Methods of treating neurological and psychiatric disorders
TWI638654B (zh) 用以治療中樞神經系統疾病之包含苯甲酸鹽化合物及鞣酸的組合物
WO2020033960A1 (en) Substituted Dihydroxyflavone Derivatives, Compositions, and Methods Related Thereto
HK1259816B (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
HK1259816A1 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
HK40052432B (en) Heterocyclic flavone derivatives, compositions, and methods related thereto
HK40052432A (en) Heterocyclic flavone derivatives, compositions, and methods related thereto

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161020

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190206

R150 Certificate of patent or registration of utility model

Ref document number: 6479670

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250